Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone

Publisher Website
Google Scholar
Abstract
A 24 h intravenous dosing regimen of amiodarone was designed to reach a peak plasma concentration at 1 h and to maintain the concentration above a certain level during the infusion period A randomized, open-label, digoxin-controlled study was undertaken to observe the efficacy and safety of the dosing regimen of amiodarone in treating recent-onset, persistent, atrial fibrillation and flutter with ventricular rates above 130 beats. min−1. Fifty patients with a mean age of 70 ± 7 (SD) years were enrolled and randomly assigned to receive either amiodarone intravenously (n=26) or digoxin (n=24). Amiodarone HCl was infused over 24 h according to the following regimen: 5 mg. min−1, 3 mg. min−1, 1 mg. min−1 and 0.5 mg. min−1 for 1, 3, 6 and 14 h, respectively, for a 70-kg subject. Digoxin (0.013 mg. kg−1) was infused in three divided doses, each dose 2 h apart and infused over 30 min. The mean heart rates in the amiodarone group decreased significantly from 157 ± 20 beats. min−1 to 122 ± 25 beats. min−1 after 1 h (P−1 after 6 h (PPP=0.0048). Digoxin, while not as effective as amiodarone in the treatment of recent-onset atrial fibrillation and flutter, appears to be safer. Therefore, we suggest the use of digoxin as the first line drug for the type of patients that formed the basis of the current study and reserve amiodarone for refractory cases or those in whom digoxin is not suitable.

This publication has 0 references indexed in Scilit: